Sheri Tempel, CSC-AD Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 7920 Crisfield Hwy, Westover, MD 21871 Phone: 443-523-1790 Fax: 410-651-3189 |
Yvonne Harris, CAC-AD Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 7920 Crisfield Hwy, Westover, MD 21871 Phone: 443-523-1790 Fax: 410-651-3189 |
Lakkisha Dryden, CSC-AD Counselor Medicare: Not Enrolled in Medicare Practice Location: 7920 Crisfield Hwy, Westover, MD 21871 Phone: 443-523-1790 Fax: 410-651-3189 |
Michael Anderton, CAC-AD Counselor Medicare: Not Enrolled in Medicare Practice Location: 7920 Crisfield Hwy, Westover, MD 21871 Phone: 443-523-1790 Fax: 410-651-3189 |
Matey Barker, LCADC, LGSW Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 7920 Crisfield Hwy, Westover, MD 21871 Phone: 443-523-1792 Fax: 410-651-3189 |
News Archive
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.
Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis headquartered in Odense, Denmark.
The first day of winter is Wednesday, December 21, and many states are bracing for a season of snow and ice. Broken bones from snowboarding and sledding top the list of common visits to the Emergency Department (ED) during the winter months. According to the Centers for Disease Control and Prevention, one-quarter of all emergency hospital visits are attributed to snowboarding accidents, and half of all cases were for broken bones and sprains.
A patient from Birmingham is the first person to be recruited into a new worldwide study to test new treatments for a potentially life-threatening kidney condition called IgA nephropathy.
› Verified 9 days ago